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ABSTRACT 
1,3-dipolar cycloaddition of arylnitrile oxides with allyl ester prepared from eugenol afforded new chiral isoxazolines in 
good yields. The chemical structure of this compounds was characterized by 
1
H NMR,
13
C NMR, 2D NMR and TOF-MS 
analysis. All the cycloadducts were obtained through a regiospecific and stereospecific pathway and all cases, only one 
isomer was isolated, as established by unambiguous NMR analysis. 
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INTRODUCTION  
Heterocyclic; compounds have a wide range of applications in synthetic organic chemistry. Especially, isoxazolines: are of 
considerable interest due to their versatile applications in pharmaceutical and agrochemical fields. Isoxazoline derivatives: 
have been reported to possess anti influenza virus,[1] glycoprotein IIb/IIIa receptor antagonists,[2] antidiabetic,[3] 
antitumour,[4] antifungal,[5] analgesic, anti-inflammatory,[6] spermicidal and anti HIV,[7] β-adrenergic receptor 
antagonist,[8] antistress[9] and anticancer properties.[10]  
In fact, the combrestatine A-4, analogous 1-3 and the Avicine 4 compound derived from isoxazolines possess anti-cancer 
activities.[11] 
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Figure 1- Representative examples of anti-cancer isoxazoline derivatives. 
The 1,3-dipolar cycloaddition reactions represent: one of the best method, for the preparation of five-membered 
heterocycles,[12]
 
and natural products.[13] In particular, the 1,3-dipolar cycloaddition: of nitrile oxides with alkenes and 
alkynes afforded isoxazolines, which are used as intermediates for the synthesis of-amino alcohols and alkaloids.[14,15]
  
In order,, to increase, the activities of the cycloadducts, we have used the eugenol [4-allyl-2methoxyphenol] as a 
precursseur of the dipolarophiles: because it is well known that ,this natural compound, have different biological activities: 
such as antispasmodic,[16]
 
antipyretic,[17] anti-inflammatory,[18] and antibacterial activities.[19]
 
Herein, we report :an efficient and practical procedure for the preparation of new optically pure isoxazolines 7(ad-cf) via 
the 1,3-dipolar cycloaddition of the arylnitrile oxides with esters, synthesized from eugenol and having a terminal double 
bond. The reaction was carried out in toluene at 80 ° C without a catalyst. 
Results and discussion 
Dipolarophiles 5(a-c) were prepared in two steps (Scheme1). The first one concern the synthesis of the N-protected 
aminoacids. The condensation of the later compounds with eugenol gave the corresponding esters.[20] 
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Scheme 1- Synthesis of the optically pure esters derived from eugenol and amino acid. 
Arylnitrile oxides were easily generated in situ from benzohydroxyaminoyl chlorides 6(d-f) with triethylamine in toluene 
according to a known procedure.[21] The cycloaddition reaction of dipolarophiles 5(a-c) with the arylnitrile oxides at reflux 
of toluene for 48h (Scheme2) afforded the isoxazolines 7(ad-cf) with good yields as indicated in table 1.  
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Scheme 2-1,3-Dipolar cycloaddition reaction of benzohydroxyaminoyl chlorides 6(d-f) with allyl esters 5(a-c). 
 
Table 1. Yields of cycloadducts 3(ad-cf) 
Entry R R’ R” Cycloadducts Yields % 
1 CH3 CH3 H 3ad 58% 
2 CH3 OCH3 H 3ae 72% 
3 CH3 OC2H5 OCH3 3af 61% 
4 i-Pr CH3 H 3bd 62% 
5 i-Pr OCH3 H 3be 60% 
6 i-Pr OC2H5 OCH3 3bf 65% 
7 CH2-i-Pr CH3 H 3cd 60% 
8 CH2-i-Pr OCH3 H 3ce 68% 
9 CH2-i-Pr OC2H5 OCH3 3cf 62% 
Regiochemistry and stereochemistry of the cycloaddition 
Two possible regioisomers: I and II, can be theoretically formed (Scheme 3) [22]. In practice, we have obtained: only one 
product as evidenced by TLC and 
1
H NMR examination of the crude mixture. Cycloadducts 7(ad-cf) have been purified by 
a column chromatography, and characterized by NMR (
1
H and 
13
C). Based on the literature, [23] and the 
13
C NMR, we 
can conclude: that the new cycloadducts possess: the same stereochemistry as detailed below. The cycloaddition of the 
amino esters 7(ad-cf) with the arylnitrile oxides: led to new cycloadducts, having a new chiral center: the quaternary 
carbon, linked to the substituted phenyl, group of the isoxazoline ring.  
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Scheme 3- Regiochemistry of cycloaddition. 
Compound 7cd:was obtained as a yellow liquid. Its positive ES–MS showed a pseudo-molecular ion peak [M+H]
+
 at m/z = 
541 compatible, with the molecular formula C32H32N2O6. The structure, was confirmed by the disappearance in the 
1
HNMR 
spectrum of the signal at H 5.01 ppm relative to the terminal ethylenic protons and the appearance of a doublet of 
doubets signal at H 2.98(dd, 1H4’, J1= 7.8 Hz, J2= 16.5 Hz) and 3.25(dd, 1H4’’, J1= 10.2 Hz, J2= 16.8 Hz), attribuable to the 
proton H4 and the presence of a singlet at H 2.33 (s, 3H) corresponding to the methyl protons. A characteristic AA’BB’: 
pattern for aromatic hydrogens was observed in the 
1
 H NMR spectrum. Examination at 300 MHz offered an excellent 
resolution: with a doublet at H 7.14 (d, 2H, J = 8.1 Hz, H3’,5’) and a second doublet at H 7.48 (d, 2H, J = 8.1 Hz, H2’,6’). 
The 
13
C NMR spectrum, confirmed the above spectral data, by the observation of signals at 126.0 (C1’), 126.2 (C2’,6’), 
128.8 (C3’,5’) and 139.7 (C4’) ppm relative to the carbons of the p-substituted aromatic system. The same spectrum, 
    I S S N  2 3 2 1 - 8 0 7 X  
V o l u m e  1 2  N u m b e r  4  
J o u r n a l  o f  A d v a n c e s  i n  C h e m i s t r y  
4335 | P a g e                                   c o u n c i l  f o r  I n n o v a t i v e  R e s e a r c h  
F e b r u a r y  2 0 1 6                                              w w w . c i r w o r l d . c o m  
showed signals at C 80.9 and 155.9 atributable to the bearing oxygen carbon C5 and C3 of imine fonction, respectively. In 
addition, a whole set of linkages confirming the molecular structure of compound 7cd was reinforced by the HMBC 
spectrum which showed correlations: between the proton H4 and C1’, C3 , C5 and C6 as well as correlations, between H2’,6’ 
and C1’, C3 and C4’. Moreover, the regiochemistry was confirmed by the NOE, observed: between the protons H4 and the 
aromatic protons H2’,6’. Although, in this study, the novel isoxazoline derivatives 7(ad-cf) were formed as an unique 
products, indicating the regiospecificity of the reaction. Indeed, the non-formation of the other 1,5-regioisomer: may be 
explained: by a possible steric crowding and by electronic factors. 
Experimental section 
Solvents were purified by standard methods. Melting points were determined on a Buchi SMP-20 capilary apparatus and 
are uncorrected. TLC was carried out on a Merck 60F-254 precoated silica gel plates (0.25 mm) and column 
chromatography was performed with Merck silica gel (70-230 mesh). NMR spectra were recorded on a Bruker AC-300 
spectrometer (
1
H NMR at 300 MHz and 
13
C NMR at 75.5 MHz) with CDCl3 as solvent and TMS as internal standard 
reference. Et3N was purchased from Acros. All starting protected amino esters were prepared according to the 
procedure.[21]
 
In all cases, the crude amino esters was purified before use.[24] The benzohydroxyaminoyl chlorides 6(d-f) 
were prepared according to the literature procedures.[22]  
General procedure for the preparation of the new isoxazolines 
A magnetically stirred solution of amino esters (5a-c) and the appropriate precursor of the benzohydroxyaminoyl chlorides 
in dry toluene, was refluxed under nitrogen for 15 min. Et3N (2 mL) was then added and the mixture was stirred and 
refluxed for 48 h. After the filtration of the triethylamine hydrochloride, the solvent was evaporated and the residue was 
purified by silica gel column chromatography (eluent: cyclohexane-AcOEt, 70:30).[25] 
2-methoxy-4-{[3-(4-methoxyphenyl)-4,5-dihydroisoxazol-5-yl]methyl}phenyl2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-
yl)propanoate(7ae) 
Yellow liquid (72%). 
1
H NMR (300MHz, CDCl3): d, -CH3, J = 7.2Hz), 2.81-2.88(dd, 1H, J1= 6.9 Hz, J2= 14.1 
Hz), 3.00-3.36 (m, 3H), 3.76(s,3H, -OCH3), 3.79(s,3H, -OCH3), 4.95-4.99(m, 2H), 6.74(d, 1H, aromatic, J = 7.4 Hz), 
6.87(d, 1H,aromatic, J = 7.8 Hz), 7.19-7.22(m, 2H, aromatics), 7.30(s, 1H, aromatic), 7.53-7.56(m, 2H, aromatics), 7.74-
7.76(m, 2H, aromatics), 7.87-7.90(m, 2H, aromatics),. 
13
C NMR (75.5MHz, CDCl3): 20.9(CH3), 38.9(CH2), 40.1(CH2), 
50.8(OOC-CH-N), 55.3(OCH3), 55.4(OCH3), 81.3(CH-O), 111.4(CHaromatic), 113.8(2CHaromatic), 121.5(CHaromatic), 
123.0(CHaromatic), 126.0(Caromatic), 127.6(Caromatic), 128.6(2CHaromatic), 129.0(2CHaromatic), 131.4(Caromatic), 133.8(2CHaromatic), 
137.7(Caromatic), 139.9(Caromatic), 151.2(Caromatic), 156.0(C=N), 167.4(N-C=O), 170.8(COO). TOFMS ES 
+
 for C29H26N2O7 
theoretical [M+H] 
+
: 515.1740; measured [M+H]
+
: 514.1743 
2-methoxy-4-{[3-(4-methoxyphenyl)-4,5-dihydroisoxazol-5-yl]methyl}phenyl2-(1,3 dioxo-1,3-dihydro-2H-isoindol-2-
yl)-3-methylbutanoate (7be) 
Yellow liquid (60%). 
1
H NMR (300MHz, CDCl3): d3H, -CH3, J = 6.6Hz), 1.25d3H, -CH3, J = 6.6 Hz), 2.33-
2.38(m, 2H), 2.97-3.29(m,4H), 3.73(s,3H, -OCH3), 3.75(s,3H, -OCH3), 4.87-4.90(m, 1H), 6.81-6.86(m, 2H, aromatics), 
6.99-7.02(dd, 1H,aromatic, J1= 1.5 Hz, J2= 8.1 Hz), 7.19-7.21(m, 2H, aromatics), 7.52-7.55(m, 2H, aromatics), 7.75-
7.58(m, 2H, aromatics), 7.91-7.94(m, 2H, aromatics). 
13
C NMR (75MHz, CDCl3):  20.3(CH3), 20.9(CH3), 28.0(CH), 
38.9(CH2), 40.1(CH2), 50.1(OOC-CH-N ), 55.2(OCH3), 55.4(OCH3), 81.0(CH-O), 111.4(CHaromatic), 113.0(2CHaromatic), 
122.2(CHaromatic), 123.0(CHaromatic), 126.0(Caromatic), 128.6(Caromatic), 129.0(2CHaromatic), 129.3(2CHaromatic),131.3(Caromatic), 
133.7(2CHaromatic), 137.8(Caromatic), 139.8(Caromatic), 150.4(Caromatic), 156.0(C=N), 167.2(N-C=O), 171.4(COO). TOFMS ES 
+
 
for C31H30N2O7 theoretical [M+H] 
+
: 525.2053; measured [M+H]
+
: 525.2057 
2-methoxy-4-{[3-(4-methoxyphenyl)-4,5-dihydroisoxazol-5-yl]methyl}phenyl 2-(1,3-dioxo-1,3-dihydro-2H-isoindol-
2-yl)-4-methylpentanoate (7ce) 
Yellow liquid (68%). 
1
H NMR (300MHz, CDCl3): d3H, -CH3, J = 6.6Hz), 1.03d3H, -CH3, J = 6.6 Hz), 1.59-
1.62(m,1H), 2.06-2.17(m, 2H), 2.97-3.36(m,4H), 3.79(s,3H, -OCH3), 3.89(s,3H, -OCH3), 4.93-4.98(m, 1H), 5.23-5.29(dd, 
1H, J1= 4.2 Hz, J2= 11.4 Hz), 6.72-6.88(m, 2H, aromatics), 6.99-7.02(dd, 1H,aromatic, J1= 1.5 Hz, J2= 8.1 Hz), 7.19(s, 
1H), 7.74-7.78(m, 3H, aromatics), 7.86-7.92(m, 2H, aromatics), 7.97-8.00(m, 2H, aromatics). 
13
C NMR (75.5MHz, CDCl3): 
 20.9(CH3), 21.2(CH3), 22.7(CH), 38.9(CH2), 39.0(CH2), 40.3(CH2), 50.0(OOC-CH-N), 55.4(OCH3), 55.6(OCH3), 
81.0(CH-O), 111.4(CHaromatic), 113.8(2CHaromatic), 121.5(CHaromatic), 123.0(CHaromatic), 126.0(Caromatic), 126.2(Caromatic), 
128.9(2CHaromatic), 129.0(2CHaromatic),129.7(Caromatic), 133.7(2CHaromatic), 137.8(Caromatic), 139.8(Caromatic), 150.4(Caromatic), 
156.0(C=N), 167.2(N-C=O), 170.8(COO). TOFMS ES 
+
 for C32H32N2O7 theoretical [M+H] 
+
: 557.2209; measured [M+H]
+
: 
557.2205. 
2-methoxy-4-{[3-(4-methylphenyl)-4,5-dihydroisoxazol-5-yl]methyl}phenyl 2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-
yl)propanoate (7ad) 
Yellow liquid (58%). 
1
H NMR (300MHz, CDCl3): 1.86(d, 3H,-CH3, J= 7.2 Hz), 2.39(s, 3H, -CH3), 2.84-2.91(dd, 1H, J1= 
6.9 Hz, J2= 14.1 Hz), 2.99-3.07(dd, 1H, J1= 7.8 Hz, J2= 16.5 Hz), 3.12-3.18(dd, 1H, J1= 6.3 Hz, J2= 13.8 Hz), 3.28-3.36(dd, 
1H, J1= 8.1 Hz, J2= 17.2 Hz), 3.82(s, 3H, -OCH3), 4.93-4.99(m, 1H), 5.30(q, 1H, J= 9.9 Hz ), 6.81-6.84(dd, 1H, J1= 1.5 Hz, 
J2= 8.1 Hz), 6.89(s,1H, aromatic), 7.02-7.05(dd, 1H, J1= 1.5 Hz, J2= 8.1 Hz), 7.21(d, 2H, aromatics, J= 8.1 Hz), 7.55(d,2H, 
aromatics, J= 8.1 Hz), 7.75-7.79(m,2H, aromatics),7.89-7.94(m, 2H, aromatics).
13
C NMR (75.5MHz, CDCl3):  
14.8(CH3), 20.9(CH3), 39.0(CH2), 40.4(CH2), 46.9(OOC-CH-N), 55.4(OCH3), 80.9(CH-O-N), 113.1(CHaromatic), 
113.1(CHaromatic), 119.5(CHaromatic), 123.0(2CHaromatic), 126.0(Caromatic), 126.2(CHaromatic), 128.8(2CHaromatic), 128.8(Caromatic), 
131.5(CHaromatic), 133.6(Caromatic), 135.7(Caromatic), 136.1(Caromatic), 150.4(Caromatic), 155.9(C=O), 166.8(N-C=O), 167.5(COO). 
TOFMS ES 
+
 for C29H26N2O6 theoretical [M+H] 
+
: 499.1790; measured [M+H]
+
: 499.1788.  
2-methoxy-4-{[3-(4-methylphenyl)-4,5-dihydroisoxazol-5-yl]methyl}phenyl 2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-
yl)-3-methylbutanoate (7bd) 
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Yellow liquid (62%). 
1
H NMR (300MHz, CDCl3): 0.95(d, 3He, -CH3, J= 7.3 Hz), 1.14-1.17(m, 4H), 2.27(s,3H,-CH3), 2.76-
3.29(m, 4H), 3.63(s, 3H, -OCH3), 4.76-4.79(m, 2H), 6.68-6.76(m, 2H, aromatics), 6.89-6.92(dd, 1H, aromatic, J1= 3.00 Hz, 
J2= 8.1 Hz), 7.09(d, 2H, aromatics, J= 8.1 Hz), 7.43(d, 2H, aromatics, J= 8.1 Hz), 7.65-7.68(m, 2H, aromatics), 7.80-
7.82(m, 2H, aromatics).
13
C NMR (75.5MHz, CDCl3): 18.8(CH3), 20.2(CH3), 20.9(CH3), 28.0(CH), 39.0(CH2), 40.3(CH2), 
55.2(OCH3), 57.0(OOOC-CH-N), 81.0(CH-O-N), 113.0(CHaromatic), 119.5(CHaromatic), 120.8(CHaromatic), 122.2(2CHaromatic), 
123.0(Caromatic), 125.0(2CHaromatic), 126.0(Caromatic), 126.2(2CHaromatic), 128.8(Caromatic), 131.7(Caromatic), 133.7(Caromatic), 
135.7(Caromatic), 150.4(Caromatic), 155.9(C=N), 166.4(N-C=O), 167.1(COO). TOFMS ES 
+
 for C31H30N2O6 theoretical [M+H] 
+
: 
527.2103; measured [M+H]
+
: 527.2105 
2-methoxy-4-{[3-(4-methylphenyl)-4,5-dihydroisoxazol-5-yl]methyl}phenyl 2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-
yl)-4-methylpentanoate (7cd) 
Yellow liquid (60%). 
1
H NMR (300MHz, CDCl3): d3H, -CH3, J = 6.6Hz), 0.98d3H, -CH3, J = 6.3Hz), 1.53-
1.59(m,1H), 2.04-2.13(m, 1H), 2.33(s,3H,-CH3), 2.39-2.50(m, 1H), 2.79-2.84(dd, 1H, J1= 6.6Hz, J2= 13.8 Hz), 2.92-
3.00(dd, 1H, J1= 7.8 Hz, J2= 16.5 Hz), 3.04-3.11(dd, 1H, J1= 6.3Hz, J2= 13.8 Hz), 3.21-3.30(dd, 1H, J1= 10.2 Hz, J2= 16.8 
Hz), 3.74(s,3H, -OCH3), 4.86-4.92(m, 1H), 5.18-5.23(dd, 1H, J1= 4.5 Hz, J2= 11.1 Hz), 6.75(d, 1H, J = 7.8 Hz), 6.82(s, 1H), 
6.94-6.97(dd, 1H, J1= 0.9 Hz, J2= 7.8 Hz ), 7.14(d, 2H, aromatics, J = 8.1 Hz), 7.48(d, 2H, aromatics, J = 8.1 Hz), 7.69-
7.72(m, 2H, aromatics), 7.82-7.86(m, 2H, aromatics). 
13
C NMR (75MHz, CDCl3):  20.65, 20.90, 22.67, 24.64, 36.82, 
39.08, 40.38, 50.12, 55.44, 80.99, 113.12, 120.80, 122.09, 123.01, 126.07, 126.29, 128.88, 131.41, 133.67, 135.78, 
137.96, 139.76, 150.45, 155.96, 167.14, 167.62. TOFMS ES 
+
 for C32H32N2O6 theoretical [M+H] 
+
: 541.2349; measured 
[M+H]
+
: 541.2346. 
4-{[3-(4-ethoxy-3-methoxyphenyl)-4,5-dihydroisoxazol-5-yl]methyl}-2-methoxyphenyl 2-(1,3-dioxo-1,3-dihydro-2H-
isoindol-2-yl)propanoate (7af) 
Yellow liquid (61%). 
1
H NMR (300MHz, CDCl3): 1.41(t, 3H, -CH3, J= 7.2 Hz ), 1.79(d, 3H, -CH3, J= 7.2 Hz ), 2.76-
2.83(dd, 1H, J1= 6.9 Hz, J2= 13.8 Hz), 2.90-2.98(dd, 1H, J1= 8.1 Hz, J2= 16.8 Hz), 3.02-3.09( dd, 1H, J1= 6.3 Hz, J2= 14.1 
Hz ), 3.19-3.28(dd, 1H, J1= 9.9 Hz, J2= 16.5 Hz), 3.74(s, 3H,-OCH3), 3.83(s, 3H, -OCH3), 4.06(q, 2H, -OCH2, J= 7.2 Hz), 
4.84-4.90(m, 1H), 5.22(q, 1H, J= 7.5 Hz), 6.74-6.79(m, 2H, aromatics), 6.83(s, 1H, aromatic), 6.90-6.985(m, 2H, 
aromatics), 7.29(d,1H, J= 1.5 Hz), 7.66-7.71(m, 2H, aromatics), 7.81-7.84(m, 2H, aromatics).
13
C NMR (75.5MHz, CDCl3): 
14.1(CH3), 14.8(CH3), 39.0(CH2), 40.3(CH2), 46.9(OOC-CH-N), 55.4(OCH3), 55.3(OCH3), 63.7(O-CH2), 80.9(CH-O), 
108.4(CHaromatic), 111.2(CHaromatic), 113.1(CHaromatic), 119.71(CHaromatic), 120.8(CHaromatic), 121.7(Caromatic), 122.0(Caromatic), 
122.9(2CHaromatic), 131.4(CHaromatic), 133.6(2CHaromatic), 135.8(Caromatic), 137.9(Caromatic), 148.8(Caromatic), 149.6(Caromatic), 
150.4(Caromatic), 155.7(C=N), 166.7(N-C=O), 167.5(COO). TOFMS ES 
+
 for C31H30N2O8 theoretical [M+H] 
+
: 559.2002; 
measured [M+H]
+
: 559.2006.  
4-{[3-(4-ethoxy-3-methoxyphenyl)-4,5-dihydroisoxazol-5-yl]methyl}-2-methoxyphenyl 2-(1,3-dioxo-1,3-dihydro-2H-
isoindol-2-yl)-3-methylbutanoate (7bf) 
Yellow liquid (65%). 
1
H NMR (300MHz, CDCl3): 0.96 (d, 3H, J= 6.6 Hz), 1.19 (d, 3H, -CH3, J= 6.6Hz), 1.42 (t, 3H, -CH3, 
J= 6.9 Hz ), 2.77-3.09(m, 4H), 3.19-3.28(dd, 1H, J1= 10.2 Hz, J2= 16.5 Hz), 3.23(s,3H, -OCH3), 3.67(s,3H, -OCH3), 4.07(q, 
2H,-OCH2-, J= 7.2 Hz), 4.81-4.87(m, 2H), 6.73-6.77(m, 2H, aromatics), 6.80(d, 1H16, aromatic, J= 4.2 Hz ), 6.92-6.97(m, 
2H, aromatics), 7.30(d,1H, J= 1.5Hz), 7.69-7.73(m, 2H, aromatics), 7.82-7.87(m, 2H, aromatique); 
13
C NMR (75.5MHz, 
CDCl3):  14.6(CH3), 19.3(CH3), 20.7(CH3), 28.4(CH), 39.5(CH2), 40.8(CH2), 55.7(OCH3), 55.9(OCH3), 57.5(OOC-CH-
N), 64.3(OCH2), 81.5(CH-O), 108.95(CHaromatic), 111.8(CHaromatic), 113.5(CHaromatic), 120.2(Caromatic), 121.2(CHaromatic), 
121.3(Caromatic), 122.7(CHaromatic), 123.5(CHaromatic), 131.7(CHaromatic), 134.2(CHaromatic), 136.2(Caromatic), 138.2(Caromatic), 
149.3(Caromatic), 150.1(Caromatic), 150.9(Caromatic), 156.2(C=N), 166.9(N-C=O), 167.6(COO). TOFMS ES 
+
 for C33H34N2O8 
theoretical [M+H] 
+
: 587.2315; measured [M+H]
+
: 587.2314. 
4-{[3-(4-ethoxy-3-methoxyphenyl)-4,5-dihydroisoxazol-5-yl]methyl}-2-methoxyphenyl 2-(1,3-dioxo-1,3-dihydro-2H-
isoindol-2-yl)-4-methylpentanoate (7cf) 
Yellow liquid (62%). 
1
H NMR (300MHz, CDCl3): 0.97(d, 3H, -CH3, J= 6.6 Hz), 1.00 (d, 3H, -CH3, J= 6.3Hz), 1.45 (t, 3H, 
-CH3, J= 7.2 Hz ), 1.58(m,1H), 2.03-2.47(m, 2H), 2.78-2.85(dd, 1H, J1= 6.9 Hz, J2= 14.1 Hz), 2.93-3.01(dd, 1H, J1= 7.8 Hz, 
J2= 16.5 Hz), 3.07-3.14(dd,1H, J1= 6.3 Hz, J2= 13.8 Hz), 3.23-3.28(dd, 1H, J1= 8.1 Hz, J2= 16.5 Hz), 3.77(s,3H, -OCH3), 
3.87(s,3H, -OCH3), 4.10(q, 2H,-OCH2, J= 6.9 Hz), 4.88-4.94(m, 1H), 5.20-5.25(dd, 1H, J1= 4.5 Hz, J2= 11.1 Hz), 6.76-
6.99(m, 5H, aromatics), 7.33(d,1H, J= 1.8Hz), 7.71-7.75(m, 2H, aromatics), 7.85-7.88(m, 2H, aromatics); 
13
C NMR 
(75.5MHz, CDCl3): 14.6(CH3), 21.1(CH3), 25.1(CH3), 26.9(CH), 39.5(CH2), 40.6(CH), 40.8(CH2), 50.6(OOC-C-N), 
55.9(2 OCH3), 64.3(O-CH2), 81.5(CH-O), 108.9(CHaromatic), 111.7(CHaromatic), 113.6(CHaromatic), 120.2(CHaromatic), 
121.2(CHaromatic), 121.3(CHaromatic), 122.2(Caromatic), 122.5(Caromatic), 123.5(CHaromatic), 129.0(Caromatic), 131.8(CHaromatic), 
134.1(Caromatic), 136.2(Caromatic), 138.4(Caromatic), 149.3(Caromatic)150.1(Caromatic), 156.2(C=N), 167.6(N-C=O), 168.12(COO). 
TOFMS ES 
+
 for C34H36N2O8 theoretical [M+H] 
+
: 601.2471; measured [M+H]
+
: 601.2467. 
Conclusion 
We have studied the reactivity of allyl esters 5(a–c) toward acyclic benzohydroxyaminoyl chlorides 6(d-f). All cycloadducts 
were formed in appreciable regiospecificity and chemospecificity, giving the products in good yields. The continuous 
pharmaceutical interest in the isoxazoline compounds may justify further exploration of these results in the 
pharmacological field. 
ACKNOWLEDGMENTS 
The authors are grateful to the DGRSRT (Direction Générale de la Recherche Scientifique et de la Rénovation 
Technologique) of the Tunisian Ministry of Higher Education and Scientific Research. 
    I S S N  2 3 2 1 - 8 0 7 X  
V o l u m e  1 2  N u m b e r  4  
J o u r n a l  o f  A d v a n c e s  i n  C h e m i s t r y  
4337 | P a g e                                   c o u n c i l  f o r  I n n o v a t i v e  R e s e a r c h  
F e b r u a r y  2 0 1 6                                              w w w . c i r w o r l d . c o m  
REFERENCES 
 [1] Gaonkar S. L., Rai L. K. M., Prabhuswamy B., Synthesis of novel 3-[5-ethyl-2-(2-phenoxy-ethyl)- pyridin]-5-substituted 
isoxazoline libraries via 1,3-dipolar cycloaddition and evaluation of antimicrobial activities, Med. Chem. Res. 15 (2007) 
407. 
[2] Basappa M., Sadashiva P., Mantelingu K., Nanjunda S. S., Rangappa K. S., Solution-phase synthesis of novel Δ2-
isoxazoline libraries via 1,3-dipolar cycloaddition and their antifungal properties, Bioorg. Med. Chem. 11 (2003) 4539. 
[3] Ahmad G., Mishra P. K., Gupta P., Yadav P. P., Tiwari P., Tamrakar A. K., Srivastava A. K., Maurya R., 
Synthesis of novel benzofuran isoxazolines as protein tyrosine phosphatase 1B inhibitors, Bioorg. Med. Chem. Lett. 
16 (2006) 2139. 
[4] Conti P., Dallanoce C., Amici M. D., Micheli C. D., Klotz K. N., synthesis of new Δ2-isoxazoline derivatives and their 
pharmacological characterization as β-adrenergic receptor antagonists, Bioorg. Med. Chem. 6 (1998) 401. 
[5] Kai H., Matsumoto H., Hattori N., Takase A., Fujiwara T., Sugimoto H., Anti-influenza Virus Activities of 2-Alkoxyimino-
N-(2-isoxazolin-3-ylmethyl)acetamides, Bioorg. Med. Chem. Lett. 11 (2001) 1997. 
[6] Srivastava S., Bajpai L. K., Batra S., Bhaduri A. P., Maikhuri J. P., Gupta G., In search of new chemical entities with 
spermicidal and anti-HIV activities, Bioorg. Med. Chem. 7 (1999) 2607. 
[7] Ichiba T., Scheuer P. J., Borges K. M., Three bromotyrosine derivatives, one terminating in an unprecedented 
diketocyclopentenylidene enamine, J. Org. Chem. 58 (1993) 4149. 
[8] Habeeb A. G., Rao P. N., Knaus E. E., Design and Synthesis of 4,5-Diphenyl-4-isoxazolines:  Novel Inhibitors of 
Cyclooxygenase-2 with Analgesic and Antiinflammatory Activity, J. Med. Chem. 44 (2001) 2921. 
[9] Antczak C., Bauvois B., Monneret C., Florent, A new acivicin prodrug designed for tumor-Targeted delivery, Bioorg. 
Med. Chem. 9 (2001) 2843. 
[10] Maurya R., Ahmad A., Gupta P., Chand k., Kumar M., Preceti R. J., Rasheed N., Palit G., Synthesis of novel 
isoxazolines via 1,3-dipolar cycloaddition and evaluation of anti-stress activity, Med. Chem. Res. 20(2011) 139. 
[11] Simoni D., Grisolia G., Giarmini G., Roberti M., Rondanin R., Piccagli L., Baruchello R., Rossi M., Romagnoli R., 
Invidiata F. P., Grimaudo S., Jung M. K., Hamel E., Gebbia N., Crosta L., Abbadessa V., Cristina A. D., Dusonchet L., Meli 
M., Tolomeo M., Heterocyclic and Phenyl Double-Bond-Locked Combretastatin Analogues Possessing Potent Apoptosis-
Inducing Activity in HL60 and in MDR Cell Lines, J. Med. Chem. 48 (2005) 723-736. 
[12] Huisgen R., 1,3-Dipolar Cycloadditions. Past and Future,  Angew. Chem., Int. Ed. Engl., 2 (1963) 565–598. 
[13]
 
Frederickson M., Optically active isoxazolidines via asymmetric cycloaddition reactions of nitrones with alkenes: 
applications in organic synthesis, Tetrahedron, 53 (1997) 403–425. 
[14] For a general review of this area see: (a) Tufariello J. J., 1,3-Dipolar Cycloaddition Chemistry In Padwa, A., Ed.; 
Wiley: New York, 1984; (b) Torssell K. B. G., Nitrile Oxides, Nitrones and Nitronates in Organic Synthesis;VCH: New York, 
1988. 
[15] (a) Seerden J. P. G., Boeren M. M. M., Scheeren H. W., 1,3-Dipolar cycloaddition reactions of nitrones with alkyl vinyl 
ethers catalyzed by chiral oxazaborolidines, Tetrahedron, 53(1997) 11843-11852; (b) Gothelf K. V., Jørgensen K. A., 
Asymmetric 1,3-Dipolar Cycloaddition Reactions, Chem. Rev., , 98 (1998) 863–910. 
[16] Wagner H., Jurcic K., Deininger R., Planta Med., 1979, 37, 9–14. 
[17] Feng J., Lipton J. M., Eugenol: Antipyretic activity in rabbits, Neuropharmacology, 26 (1987) 1775–1778. 
[18] Hume W. R., Effect of Eugenol on Constrictor Responses in Blood Vessels of the Rabbit Ear, J. Dent. Res. , 62 
(1983) 1013–1015. 
[19] Shattuck J., Shreve C., Solomon S., Enantioselective Synthesis of Imperanene, a Platelet Aggregation Inhibitor ,Org 
Lett. 3 (2001) 3021. 
[20] Essersi A. , Touati R., Ben Hassine B., Diastereoselective Synthesis of γ-Phthalimido-β-Hydroxy Esters and N-
Protected 4-Amino-1,3-Diols Starting from Natural α-Amino Acids, Letters in Organic Chemistry, 7 (2010) 69. 
[21] Liu K. C., Shelton R. B., Howe R. K., A particularly convenient preparation of benzohydroximinoyl chlorides (nitrile 
oxide precursors), J. Org. Chem. 45 (1980) 3916; Huisgen R., Mack N., 1.3 Dipolare additionen der nitriloxyde an 
carbonylverbindungen, Tetrahedron Lett. 2 (1961) 583.  
[22] Lorand K., Melinda N., Enik F., Reijo S., Ferenc F., Synthesis of novel isoxazoline-fused cispentacin 
stereoisomers, Tetrahedron Lett. 50 (2009) 2605-2608. 
[23] Juneau S., Synthèse asymétrique de 2-isoxazolines en vue de la synthèse totale de la négamycine, Université du 
Québec à Montréal, 2008.  
[24] Lahouar G., Touati R., Khamri S., Marrot J., Ben Hassine B., Asymmetric synthesis and spectroscopic 
characterization of various N-substituted phthaloyl and tosyl derivatives, Journal of Chemical and Pharmaceutical 
Research,7 (2015) 283-288. 
[25] Jegham N., Kacem Y., Ben Hassine B., Regioselective Synthesis and Structure of New Spiro-isoquinolinedione 
Derivatives, Heterocycles, 81 (2010) 707-715. 
Figures captions 
Figure 1- Representative examples of anti-cancer isoxazoline derivatives. 
Scheme 1- Synthesis of the optically pure esters derived from eugenol and amino acid. 
Scheme 2-1,3-Dipolar cycloaddition reaction of benzohydroxyaminoyl chlorides 6(d-f) with allyl esters 5(a-c). 
Scheme 3- Regiochemistry of cycloaddition. 
 
